![Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer](https://oncodaily.com/pub/uploads/2024/04/IMG_2328-e1714423380475.jpeg)
Photo taken from Matthew Goetz/LinkedIn
Apr 29, 2024, 14:18
Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer
Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:
“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:
Is the benefit of Abemacicib compromised in those that require dose reductions?
A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.
Clinicians should utilize dose modifications when necessary to maximize adherence.”
Additional information.
Source: Matthew Goetz/LinkedIn
Aug 16, 2024, 20:23